[1] |
XU LP, LU PH, WU DP, et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group[J]. Bone Marrow Transplant, 2021, 56(12): 2940-2947. DOI: 10.1038/s41409-021-01431-6.
|
[2] |
INAMOTO Y, VALDÉS-SANZ N, OGAWA Y, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT[J]. Bone Marrow Transplant, 2019, 54(5): 662-673. DOI: 10.1038/s41409-018-0340-0.
|
[3] |
CHHABRA S, JERKINS JH, CONTO JE, et al. Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease[J]. Leuk Lymphoma, 2020, 61(4): 869-874. DOI: 10.1080/10428194.2019.1695049.
|
[4] |
KEZIC JM, WIFFEN S, DEGLI-ESPOSTI M. Keeping an 'eye' on ocular GVHD[J]. Clin Exp Optom, 2021: 1-8. DOI: 10.1080/08164622.2021.1971047.
|
[5] |
QIU Y, HONG J, PENG R. Manifestation of clinical categories of ocular graft-versus-host disease[J]. J Ophthalmol, 2018: 6430953. DOI: 10.1155/2018/6430953.
|
[6] |
OGAWA Y, OKAMOTO S, WAKUI M, et al. Dry eye after haematopoietic stem cell transplantation[J]. Br J Ophthalmol, 1999, 83(10): 1125-1130. DOI: 10.1136/bjo.83.10.1125.
|
[7] |
GIANNACCARE G, BONIFAZI F, SESSA M, et al. Ocular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice[J]. Eye (Lond), 2017, 31(10): 1417-1426. DOI: 10.1038/eye.2017.78.
|
[8] |
BERCHICCI L, RABIOLO A, MARCHESE A, et al. Ocular chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in an Italian referral center[J]. Ocul Surf, 2018, 16(3): 314-321. DOI: 10.1016/j.jtos.2018.04.001.
|
[9] |
WANG JCC, MUSTAFA M, TEICHMAN JC, et al. Risk factors associated with severity of dry eye syndrome in ocular graft-versus-host disease[J]. Can J Ophthalmol, 2020, 55(5): 366-372. DOI: 10.1016/j.jcjo.2020.04.013.
|
[10] |
PELLEGRINI M, BERNABEI F, BARBATO F, et al. Incidence, risk factors and complications of ocular graft-versus-host disease following hematopoietic stem cell transplantation[J]. Am J Ophthalmol, 2021, 227: 25-34. DOI: 10.1016/j.ajo.2021.02.022.
|
[11] |
JAGASIA MH, GREINIX HT, ARORA M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅰ. the 2014 Diagnosis and Staging Working Group report[J]. Biol Blood Marrow Transplant, 2015, 21(3): 389-401. DOI: 10.1016/j.bbmt.2014.12.001.
|
[12] |
OGAWA Y, KIM SK, DANA R, et al. International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part Ⅰ)[J]. Sci Rep, 2013, 3: 3419. DOI: 10.1038/srep03419.
|
[13] |
RAPOPORT Y, FREEMAN T, KOYAMA T, et al. Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group diagnostic criteria as a chronic ocular GVHD-specific metric[J]. Cornea, 2017, 36(2): 258-263. DOI: 10.1097/ICO.0000000000001109.
|
[14] |
WOLFF D, RADOJCIC V, LAFYATIS R, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅳ. the 2020 highly morbid forms report[J]. Transplant Cell Ther, 2021, 27(10): 817-835. DOI: 10.1016/j.jtct.2021.06.001.
|
[15] |
李植源. 角膜神经性疼痛研究新进展[J]. 眼科学报, 2021, 36(5): 356-363. DOI: 10.3978/j.issn.1000-4432.2021.04.05.LI ZY. New progress in the study of neuropathic corneal pain[J]. Eye Sci, 2021, 36(5): 356-363. DOI: 10.3978/j.issn.1000-4432.2021.04.05.
|
[16] |
NAIR S, VANATHI M, MUKHIJA R, et al. Update on ocular graft-versus-host disease[J]. Indian J Ophthalmol, 2021, 69(5): 1038-1050. DOI: 10.4103/ijo.IJO_2016_20.
|
[17] |
廖颖琳. 地夸磷索钠治疗干眼的作用机制及其临床应用[J]. 眼科学报, 2021, 36(4): 288-292. DOI: 10.3978/j.issn.1000-4432.2021.03.012.LIAO YL. Mechanism and clinical application of diquafosol tetrasodium in dry eye treatment[J]. Eye Sci, 2021, 36(4): 288-292. DOI: 10.3978/j.issn.1000-4432.2021.03.012.
|
[18] |
SHAMLOO K, BARBARINO A, ALFURAIH S, et al. Graft versus host disease-associated dry eye: role of ocular surface mucins and the effect of rebamipide, a mucin secretagogue[J]. Invest Ophthalmol Vis Sci, 2019, 60(14): 4511-4519. DOI: 10.1167/iovs.19-27843.
|
[19] |
SINGH RB, YUNG A, COCO G, et al. Efficacy and retention of silicone punctal plugs for treatment of dry eye in patients with and without ocular graft-versus-host-disease[J]. Ocul Surf, 2020, 18(4): 731-735. DOI: 10.1016/j.jtos.2020.07.018.
|
[20] |
BEYLERIAN M, LAZARO M, MAGALON J, et al. Autologous serum tears: long-term treatment in dry eye syndrome[J]. J Fr Ophtalmol, 2018, 41(3): 246-254. DOI: 10.1016/j.jfo.2017.11.008.
|
[21] |
MARTÍNEZ-CARRASCO R, SÁNCHEZ-ABARCA LI, NIETO-GÓMEZ C, et al. Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD[J]. Ocul Surf, 2019, 17(2): 285-294. DOI: 10.1016/j.jtos.2019.01.001.
|
[22] |
ZHOU T, HE C, LAI P, et al. MiR-204-containing exosomes ameliorate GVHD-associated dry eye disease[J]. Sci Adv, 2022, 8(2): eabj9617. DOI: 10.1126/sciadv.abj9617.
|
[23] |
张暖, 罗晓慧. 间充质干细胞在眼表疾病治疗中的应用[J]. 眼科学报, 2021, 36(4): 299-305. DOI: 10.3978/j.issn.1000-4432.2020.07.11.ZHANG N, LUO XH. Application of mesenchymal stem cells in the treatment of ocular diseases[J]. Eye Sci, 2021, 36(4): 299-305. DOI: 10.3978/j.issn.1000-4432.2020.07.11.
|
[24] |
PERIC Z, SKEGRO I, DURAKOVIC N, et al. Amniotic membrane transplantation-a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus-host disease[J]. Bone Marrow Transplant, 2018, 53(11): 1466-1469. DOI: 10.1038/s41409-018-0140-6.
|
[25] |
JARADE EF, EL RAMI H, ABDELMASSIH Y, et al. Chronic ocular GVHD: limbal and conjunctival stem cell allografts from the same hematopoietic stem cell donor[J]. Int J Ophthalmol, 2018, 11(9): 1569-1572. DOI: 10.18240/ijo.2018.09.24.
|
[26] |
CHEUNG AY, GENEREUX BM, AUTERI NJ, et al. Conjunctival-limbal allografts in graft-versus-host disease using same HLA-identical bone marrow transplantation donor[J]. Can J Ophthalmol, 2018, 53(3): e120-e122. DOI: 10.1016/j.jcjo.2017.09.004.
|
[27] |
BRUSCOLINI A, GHARBIYA M, SACCHETTI M, et al. Involvement of ocular surface in graft-versus-host disease: an update from immunopathogenesis to treatment[J]. J Cell Physiol, 2021, 236(9): 6190-6199. DOI: 10.1002/jcp.30304.
|
[28] |
COOKE KR, LUZNIK L, SARANTOPOULOS S, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2017, 23(2): 211-234. DOI: 10.1016/j.bbmt.2016.09.023.
|
[29] |
OGAWA Y, KAWAKAMI Y, TSUBOTA K. Cascade of inflammatory, fibrotic processes, and stress-induced senescence in chronic GVHD-related dry eye disease[J]. Int J Mol Sci, 2021, 22(11): 6114. DOI: 10.3390/ijms22116114.
|
[30] |
KUSNE Y, TEMKIT M, KHERA N, et al. Conjunctival subepithelial fibrosis and meibomian gland atrophy in ocular graft-versus-host disease[J]. Ocul Surf, 2017, 15(4): 784-788. DOI: 10.1016/j.jtos.2017.08.002.
|
[31] |
NAIR S, VANATHI M, MAHAPATRA M, et al. Tear inflammatory mediators and protein in eyes of post allogenic hematopoeitic stem cell transplant patients[J]. Ocul Surf, 2018, 16(3): 352-367. DOI: 10.1016/j.jtos.2018.04.007.
|
[32] |
YEHUDAI-OFIR D, HENIG I, ZUCKERMAN T. Aberrant B cells, autoimmunity and the benefit of targeting B cells in chronic graft-versus-host disease[J]. Autoimmun Rev, 2020, 19(4): 102493. DOI: 10.1016/j.autrev.2020.102493.
|
[33] |
ZHANG C, TODOROV I, ZHANG Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations[J]. Blood, 2006, 107(7): 2993-3001. DOI: 10.1182/blood-2005-09-3623.
|
[34] |
NAKASONE H, TIAN L, SAHAF B, et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans[J]. Blood, 2015, 125(20): 3193-3201. DOI: 10.1182/blood-2014-11-613323.
|
[35] |
YANG K, CHEN Y, QI H, et al. Anti-Ro52 autoantibodies are related to chronic graft-vs.-host disease after allogeneic hematopoietic stem cell transplantation[J]. Front Immunol, 2020, 11: 1505. DOI: 10.3389/fimmu.2020.01505.
|
[36] |
SVEGLIATI S, OLIVIERI A, CAMPELLI N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease[J]. Blood, 2007, 110(1): 237-241. DOI: 10.1182/blood-2007-01-071043.
|
[37] |
BRINK R. Regulation of B cell self-tolerance by BAFF[J]. Semin Immunol, 2006, 18(5): 276-283. DOI: 10.1016/j.smim.2006.04.003.
|
[38] |
SAMY E, WAX S, HUARD B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases[J]. Int Rev Immunol, 2017, 36(1): 3-19. DOI: 10.1080/08830185.2016.1276903.
|
[39] |
JIA W, POE JC, SU H, et al. BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation[J]. Blood, 2021, 137(18): 2544-2557. DOI: 10.1182/blood.2020008040.
|
[40] |
SARANTOPOULOS S, STEVENSON KE, KIM HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease[J]. Clin Cancer Res, 2007, 13(20): 6107-6114. DOI: 10.1158/1078-0432.CCR-07-1290.
|
[41] |
SARANTOPOULOS S, STEVENSON KE, KIM HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease[J]. Blood, 2009, 113(16): 3865-3874. DOI: 10.1182/blood-2008-09-177840.
|
[42] |
FLYNN R, ALLEN JL, LUZNIK L, et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease[J]. Blood, 2015, 125(26): 4085-4094. DOI: 10.1182/blood-2014-08-595470.
|
[43] |
POE JC, JIA W, DI PAOLO JA, et al. Syk inhibitor entospletinib prevents ocular and skin GVHD in mice[J]. JCI Insight, 2018, 3(19): e122430. DOI: 10.1172/jci.insight.122430.
|
[44] |
KUZMINA Z, GREINIX HT, WEIGL R, et al. Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia[J]. Blood, 2011, 117(7): 2265-2274. DOI: 10.1182/blood-2010-07-295766.
|
[45] |
SARANTOPOULOS S, RITZ J. Aberrant B-cell homeostasis in chronic GVHD[J]. Blood, 2015, 125(11): 1703-1707. DOI: 10.1182/blood-2014-12-567834.
|
[46] |
POE JC, JIA W, SU H, et al. An aberrant Notch2-BCR signaling axis in B cells from patients with chronic GVHD[J]. Blood, 2017, 130(19): 2131-2145. DOI: 10.1182/blood-2017-05-782466.
|
[47] |
DEBUREAUX PE, DE MASSON A, BATTISTELLA M, et al. Chronic graft-versus-host disease and inhibition of interleukin-17: proof of concept in humans[J]. Br J Dermatol, 2020, 182(4): 1038-1041. DOI: 10.1111/bjd.18214.
|
[48] |
PAULSEN F. Functional anatomy and immunological interactions of ocular surface and adnexa[J]. Dev Ophthalmol, 2008, 41: 21-35. DOI: 10.1159/000131068.
|
[49] |
STEVEN P, SCHWAB S, KIESEWETTER A, et al. Disease-specific expression of conjunctiva associated lymphoid tissue (CALT) in mouse models of dry eye disease and ocular allergy[J]. Int J Mol Sci, 2020, 21(20): 7514. DOI: 10.3390/ijms21207514.
|
[50] |
ROZMUS J, KARIMINIA A, ABDOSSAMADI S, et al. Comprehensive B cell phenotyping profile for chronic graft-versus-host disease diagnosis[J]. Biol Blood Marrow Transplant, 2019, 25(3): 451-458. DOI: 10.1016/j.bbmt.2018.11.007.
|
[51] |
AQRAWI LA, GALTUNG HK, GUERREIRO EM, et al. Proteomic and histopathological characterisation of sicca subjects and primary Sjögren's syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers[J]. Arthritis Res Ther, 2019, 21(1): 181. DOI: 10.1186/s13075-019-1961-4.
|
[52] |
HU B, QIU Y, HONG J. Tear cytokine levels in the diagnosis and severity assessment of ocular chronic graft-versus-host disease(GVHD)[J]. Ocul Surf, 2020, 18(2): 298-304. DOI: 10.1016/j.jtos.2019.12.005.
|